Novavax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2020

Rhea-AI Summary

Novavax, Inc. (Nasdaq: NVAX) announced the presentation of its COVID-19 vaccine, NVX-CoV2373, at the virtual 2020 World Vaccine Congress Europe from October 19-21, 2020. Gregory M. Glenn, M.D., President of Research & Development, will discuss the recombinant nanoparticle vaccine platform. NVX-CoV2373 is engineered from the SARS-CoV-2 genetic sequence and incorporates Novavax's Matrix-M™ adjuvant to enhance immune response. The vaccine has shown promising results in preclinical trials and is in Phase 1 and Phase 3 clinical evaluations, supported by $2 billion in funding for its global vaccine program.

Positive

• NVX-CoV2373 has shown robust antibody responses superior to human convalescent sera in Phase 1 trials.
• The vaccine candidate is undergoing Phase 3 trials in the UK, with additional Phase 2 studies in South Africa, the US, and Australia.
• $2 billion in funding secured for the global coronavirus vaccine program, including $388 million from CEPI.

Negative

• None.

GAITHERSBURG, Md., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D, President of Research & Development, will present on NVX-CoV2373, the Company’s COVID-19 vaccine, at the 2020 World Vaccine Congress Europe. The Congress takes place virtually October 19 - 21, 2020.

Presentation Title:	Recombinant nanoparticle COVID-19 vaccine: Platform technology for Emerging Infectious Diseases (EID)
Time:	14:10 CET/8:10 am ET

For more information on the Congress or to register, please click here.

About NVX-CoV2373
NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and cannot replicate, nor can it cause COVID-19. In preclinical trials, NVX-CoV2373 demonstrated induction of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. In the Phase 1 portion of its Phase 1/2 clinical trial, NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. NVX-CoV2373 is also being evaluated in a Phase 3 trial in the UK and two ongoing Phase 2 studies that began in August; a Phase 2b trial in South Africa, and a Phase 1/2 continuation in the U.S. and Australia. Novavax has secured $2 billion in funding for its global coronavirus vaccine program, including up to $388 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI).

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is undertaking clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:
Investors
Erika Trahan
ir@novavax.com
240-268-2022

Media
Brandzone/KOGS Communication
Edna Kaplan
kaplan@kogspr.com
617-974-8659

FAQ

What is NVX-CoV2373 and its significance for Novavax (NVAX)?

NVX-CoV2373 is Novavax's COVID-19 vaccine candidate, designed using recombinant nanoparticle technology, aimed at generating an effective immune response.

When is Novavax presenting at the World Vaccine Congress Europe?

Gregory M. Glenn, M.D., will present on October 20, 2020, at 14:10 CET/8:10 am ET.

How much funding has Novavax secured for its COVID-19 vaccine development?

Novavax has secured $2 billion for its global coronavirus vaccine program, including $388 million from CEPI.

What are the trial phases for NVX-CoV2373?

NVX-CoV2373 is currently in Phase 1/2 and Phase 3 clinical trials.

What technology is used in the development of NVX-CoV2373?

The vaccine uses recombinant nanoparticle technology and a patented saponin-based Matrix-M™ adjuvant to enhance immune response.